Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

A 5‑FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry In Vitro and In Vivo

  • Adam, Catherine
  • Rubio Ruiz, Belén|||0000-0003-4720-6578
We are grateful to the EPSRC (EP/N021134/1) for funding. T.L.B. thanks the CMVM of the University of Edinburgh (Principal's scholarship), and B.R.-R. thanks the EC (H2020MSCA-IF-2014-658833, ChemoBOOM) for financial support. A.U.-B. and D.J.B. thank Medical Research Scotland (PHD-1046-2016) for funding. We acknowledge support from the MRC Confidence in Concept scheme (MRC/CIC6/52) and EPSRC Impact Acceleration Account (PIII024)., 5-Fluorouracil (5-FU) is an antineoplastic antimetabolite that is widely administered to cancer patients by bolus injection, especially to those suffering from colorectal and pancreatic cancer. Because of its suboptimal route of administration and dose-limiting toxicities, diverse 5-FU prodrugs have been developed to confer oral bioavailability and increase the safety profile of 5-FU chemotherapy regimens. Our contribution to this goal is presented herein with the development of a novel palladium-activated prodrug designed to evade the metabolic machinery responsible for 5-FU anabolic activation and catabolic processing. The new prodrug is completely innocuous to cells and highly resistant to metabolization by primary hepatocytes and liver S9 fractions (the main metabolic route for 5-FU degradation), whereas it is rapidly converted into 5-FU in the presence of a palladium (Pd) source. In vivo pharmokinetic analysis shows the prodrug is rapidly and completely absorbed after oral administration and exhibits a longer half-life than 5-FU. In vivo efficacy studies in a xenograft colon cancer model served to prove, for the first time, that orally administered prodrugs can be locally converted to active drugs by intratumorally inserted Pd implants., UK Research & Innovation (UKRI) Engineering & Physical Sciences Research Council (EPSRC) EP/N021134/1, CMVM of the University of Edinburgh, European Commission European Commission Joint Research Centre H2020MSCA-IF-2014-658833, Medical Research Scotland PHD-1046-2016, UK Research & Innovation (UKRI) Medical Research Council UK (MRC) MRC/CIC6/52 UK Research & Innovation (UKRI), Engineering & Physical Sciences Research Council (EPSRC) PIII024
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

In Cellulo Bioorthogonal Catalysis by Encapsulated AuPd Nanoalloys: Overcoming Intracellular Deactivation

  • Rubio Ruiz, Belén|||0000-0003-4720-6578
  • Ortega Liébana, M. Carmen
  • Valero Griñán, María Teresa|||0000-0002-3625-311X
Bioorthogonal metallocatalysis has opened up a xenobiotic route to perform nonenzymatic catalytic transformations in living settings. Despite their promising features, most metals are deactivated inside cells by a myriad of reactive biomolecules, including biogenic thiols, thereby limiting the catalytic functioning of these abiotic reagents. Here we report the development of cytocompatible alloyed AuPd nanoparticles with the capacity to elicit bioorthogonal depropargylations with high efficiency in biological media. We also show that the intracellular catalytic performance of these nanoalloys is significantly enhanced by protecting them following two different encapsulation methods. Encapsulation in mesoporous silica nanorods resulted in augmented catalyst reactivity, whereas the use of a biodegradable PLGA matrix increased nanoalloy delivery across the cell membrane. The functional potential of encapsulated AuPd was demonstrated by releasing the potent chemotherapy drug paclitaxel inside cancer cells. Nanoalloy encapsulation provides a novel methodology to develop nanoreactors capable of mediating new-to-life reactions in cells., UK Research & Innovation (UKRI), Engineering & Physical Sciences Research Council (EPSRC) EP/N021134/1, ERC (Advanced Grant CADENCE) ERC-2016-ADG-742684, European Commission European Commission Joint Research Centre H2020-MSCA-IF-2014-658833 H2020-MSCA-IF-2018-841990 H2020-MSCA-IF-2016-749299 H2020-MSCA-IF-2019-895664, Spanish Government RTI2018-099019-A-I00
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Nondestructive production of exosomes loaded with ultrathin palladium nanosheets for targeted bio-orthogonal catalysis

  • Sebastián, Víctor
  • Sancho‐Albero, María
  • Arruebo, Manuel
  • Pérez‐López, Ana M.
  • Rubio‐Ruiz, Belén
  • Martín-Duque, Pilar
  • Unciti-Broceta, Asier
  • Ricote, J.
The use of exosomes as selective delivery vehicles of therapeutic agents, such as drugs or hyperthermia-capable nanoparticles, is being intensely investigated on account of their preferential tropism toward their parental cells. However, the methods used to introduce a therapeutic load inside exosomes often involve disruption of their membrane, which may jeopardize their targeting capabilities, attributed to their surface integrins. On the other hand, in recent years bio-orthogonal catalysis has emerged as a new tool with a myriad of potential applications in medicine. These bio-orthogonal processes, often based on Pd-catalyzed chemistry, would benefit from systems capable of delivering the catalyst to target cells. It is therefore highly attractive to combine the targeting capabilities of exosomes and the bio-orthogonal potential of Pd nanoparticles to create new therapeutic vectors. In this protocol, we provide detailed information on an efficient procedure to achieve a high load of catalytically active Pd nanosheets inside exosomes, without disrupting their membranes. The protocol involves a multistage process in which exosomes are first harvested, subjected to impregnation with a Pd salt precursor followed by a mild reduction process using gas-phase CO, which acts as both a reducing and growth-directing agent to produce the desired nanosheets. The technology is scalable, and the protocol can be conducted by any researcher having basic biology and chemistry skills in ~3 d., We gratefully acknowledge financial support from the ERC Advanced Grant CADENCE (grant no. ERC-2016-ADG-742684) and the EPSRC (Healthcare Technology Challenge award no. EP/N021134/1). M.S.-A. thanks the Spanish Government for an FPU PhD research fellowship. B.R.-R. thanks the EC (grant no. H2020-MSCA-IF-2014–658833). V.S. acknowledges the financial support of Ministerio de Ciencia, Innovación y Universidades, Programa Retos Investigación, Proyecto REF: RTI2018-099019-A-I00. M.A. acknowledges the financial support of the ERC Consolidator Grant programme (grant no. ERC-2013-CoG-614715). P.M.-D. also thanks Instituto de Salud Carlos III (PI19/01007). We also thank CIBER-BBN, an initiative funded by the VI National R&D&i Plan 2008–2011 financed by the Instituto de Salud Carlos III and by Fondo Europeo de Desarrollo Regional (Feder) ‘Una manera de hacer Europa’, with the assistance of the European Regional Development Fund. This study is also partially funded by the Aragon Government (T57_17R p) cofounded by Feder 2014–2020 ‘Building Europe from Aragon’., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A minimally-masked inactive prodrug of panobinostat that is bioorthogonally activated by gold chemistry

  • Rubio‐Ruiz, Belén
  • Pérez‐López, Ana M.
  • Sebastián, Víctor
  • Unciti-Broceta, Asier
The recent incorporation of Au chemistry in the bioorthogonal toolbox has opened up new opportunities to deliver biologically independent reactions in living environments. Herein we report that the O-propargylation of the hydroxamate group of the potent HDAC inhibitor panobinostat leads to a vast reduction of its anticancer properties (>500-fold). We also show that this novel prodrug is converted back into panobinostat in the presence of Au catalysts in vitro and in cell culture., We gratefully acknowledge financial support from EPSRC (EP/N021134/1 and EP/S010289/1). B.R.-R. thanks the EC (grant no. H2020-MSCA-IF-2014-658833). V.S. acknowledges the financial support of Ministerio de Ciencia, Innovación y Universidades, Programa Retos Investigación, Proyecto REF: RTI2018-099019-A-I00., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bioorthogonal uncaging of cytotoxic paclitaxel through Pd nanosheet-hydrogel frameworks

  • Pérez‐López, Ana M.
  • Rubio‐Ruiz, Belén
  • Valero, Teresa
  • Contreras Montoya, Rafael
  • Álvarez de Cienfuegos, Luis
  • Sebastián, Víctor
  • Santamaría, Jesús
  • Unciti-Broceta, Asier
The promising potential of bioorthogonal catalysis in biomedicine is inspiring incremental efforts to design strategies that regulate drug activity in living systems. To achieve this, it is not only essential to develop customized inactive prodrugs and biocompatible metal catalysts but also the right physical environment for them to interact and enable drug production under spatial and/or temporal control. Toward this goal, here, we report the first inactive precursor of the potent broad-spectrum anticancer drug paclitaxel (a.k.a. Taxol) that is stable in cell culture and labile to Pd catalysts. This new prodrug is effectively uncaged in cancer cell culture by Pd nanosheets captured within agarose and alginate hydrogels, providing a biodegradable catalytic framework to achieve controlled release of one of the most important chemotherapy drugs in medical practice. The compatibility of bioorthogonal catalysis and physical hydrogels opens up new opportunities to administer and modulate the mobility of transition metal catalysts in living environs., We thank EPSRC (Healthcare Technology Challenge Award, no. EP/N021134/1) and ERC (Advanced Grant CADENCE, no. ERC-2016-ADG-742684) for funding. B.R.-R. and T.V. thank the EC for an MSC Fellowship (H2020-MSCA-IF-2014-658833 and H2020-MSCA-IF-2016-749299, respectively). R.C.M. is grateful for the support of the Vicerrectorate of Research of University of Granada. R.C.-M. and L.A.C. thank Junta de Andalucı́a (Spain) for funding project P12-FQM-790. L.A.C. thanks the Ministerio de Ciencia, Innovación y Universidades, for a Salvador de Madariaga visiting professor fellowship (PRX18/00017) and the Agencia Estatal de Investigación (Ministerio de Economia y Competitividad) and the European Regional Development Fund for cofunding project FIS2017-85954-R. V.S. acknowledges the financial support from Ministerio de Ciencia, Innovación y Universidades, Programa Retos Investigación, Proyecto REF: RTI2018-099019-A-I00., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis

  • Sancho‐Albero, María
  • Rubio‐Ruiz, Belén
  • Pérez‐López, Ana M.
  • Sebastián, Víctor
  • Martín-Duque, Pilar
  • Arruebo, Manuel
  • Santamaría, Jesús
  • Unciti-Broceta, Asier
The transformational impact of bioorthogonal chemistries has inspired new strategies for the in vivo synthesis of bioactive agents through non-natural means. Among these, palladium (Pd) catalysts have played a prominent role in the growing subfield of bioorthogonal catalysis by producing xenobiotics and uncaging biomolecules in living systems. However, delivering catalysts selectively to specific cell types still lags behind catalyst development. Here we have developed a bio-artificial device consisting of cancer-derived exosomes loaded with Pd catalysts by a method that enables the controlled assembly of Pd nanosheets directly inside the vesicles. This hybrid system mediates Pd-triggered dealkylation reactions in vitro and inside cells and displays preferential tropism for their progenitor cells. The use of Trojan exosomes to deliver abiotic catalysts into designated cancer cells creates the opportunity for a new targeted therapy modality: exosome-directed catalyst prodrug therapy, whose first steps are presented herein with the cell-specific release of the anticancer drug panobinostat., We gratefully acknowledge financial support from EPSRC (Healthcare Technology Challenge award no. EP/N021134/1) and the ERC Advanced Grant CADENCE (grant no. ERC-2016-ADG-742684). We also thank S. Irusta at the University of Zaragoza for performing X-ray photoelectron spectroscopy measurements. M.S.-A. thanks the Spanish government for an FPU PhD research fellowship. B.R.-R. thanks the EC (grant no. H2020-MSCA-IF-2014–658833). M.A. thanks the financial support of the ERC Consolidator Grant programme (grant no. ERC-2013-CoG-614715). P.M.-D. thanks AECC Fund and Refbio-Lactodermal for financial support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Gold-triggered uncaging chemistry in living systems

  • Pérez-López, Ana M.
  • Rubio‐Ruiz, Belén
  • Sebastián, Víctor
  • Adam, Catherine
  • Irusta, Silvia
  • Santamaría, Jesús
  • Unciti-Broceta, Asier
et al., Recent advances in bioorthogonal catalysis are increasing the capacity of researchers to manipulate the fate of molecules in complex biological systems. A bioorthogonal uncaging strategy is presented, which is triggered by heterogeneous gold catalysis and facilitates the activation of a structurally diverse range of therapeutics in cancer cell culture. Furthermore, this solid-supported catalytic system enabled locally controlled release of a fluorescent dye into the brain of a zebrafish for the first time, offering a novel way to modulate the activity of bioorthogonal reagents in the most fragile and complex organs., A.M.P.-L., C.A., P.M.B., and A.U.-B. are grateful to the EPSRC (EP/N021134/1), the CRUK (Pioneer Award), and the Royal Society (RG150377) for funding. B.R.-R. and T.L.B. thank the EC (H2020-MSCA-IF-2014-658833, ChemoBOOM), and the CMVM of the University of Edinburgh (Principal's scholarship), respectively, for financial support. L.H. was supported by a CRUK PhD Fellowship. D.S. thanks CRUK for a Career Establishment Award. V.S., S.I., and J.S. thank CIBER-BBN for financial support. CIBER-BBN is an initiative funded by the VI National R&D&i Plan 2008–2011 financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. V.S. and J.S. are grateful to the University of Zaragoza (Project JIUZ-2016-TEC-13). The research leading to these results has received funding from the ERC under the EU′s FP7/2007–2013 (ERC grant agreement no. [340163])., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

High-precision photothermal ablation using biocompatible palladium nanoparticles and laser scanning microscopy

  • Rubio‐Ruiz, Belén
  • Pérez-López, Ana M.
  • Bray, Thomas L.
  • Lee, Martin
  • Serrels, Alan
  • Prieto, Martín
  • Arruebo, Manuel
  • Carragher, Neil O.
  • Sebastián, Víctor
  • Unciti-Broceta, Asier
Herein, we report a straightforward method for the scalable preparation of Pd nanoparticles (Pd-NPs) with reduced inherent cytotoxicity and high photothermal conversion capacity. These Pd-NPs are rapidly taken up by cells and able to kill labeled cancer cells upon short exposure to near-infrared (NIR) light. Following cell treatment with Pd-NPs, ablated areas were patterned with high precision by laser scanning microscopy, allowing one to perform cell migration assays with unprecedented accuracy. Using coherent Raman microscopy, cells containing Pd-NPs were simultaneously ablated and imaged. This novel methodology was combined with intravital imaging to mediate microablation of cancerous tissue in tumor xenografts in mice., A.M.P.-L., N.O.C., and A.U.-B. are grateful to the EPSRC (EP/N021134/1) and the Royal Society (RG150377) for funding. B.R.-R. and T.L.B. thank the EC (H2020-MSCA-IF-2014-658833, ChemoBOOM) and the CMVM of the University of Edinburgh (Principal’s scholarship), respectively, for financial support. M.L. and A.S. acknowledge the support of CRUK (C10195/A18075 and C157/A15703, respectively). M.A. and V.S. thank CIBER-BBN for financial support. CIBER-BBN is an initiative funded by the VI National R&D&i Plan 2008-2011 financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. V.S. is grateful to the University of Zaragoza (Project JIUZ-2016-TEC-13). M.A. also acknowledges the financial support of the ERC Consolidator Grant program (ERC-2013-CoG-614715). We acknowledge the support of the Wellcome Trust Multi User Equipment Grant (WT104915MA) for the TEM studies., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis

  • Sancho-Albero, María
  • Rubio-Ruiz, Belén
  • Pérez-López, Ana M.
  • Sebastián, Víctor
  • Martín-Duque, Pilar
  • Arruebo, Manuel
  • Santamaría, Jesús
  • Unciti-Broceta, Asier
The transformational impact of bioorthogonal chemistries has inspired new strategies for the in vivo synthesis of bioactive agents through non-natural means. Among these, Pd catalysts have played a prominent role in the growing subfield of bioorthogonal catalysis by producing xenobiotics and uncaging biomolecules in living systems. However, delivering catalysts selectively to specific cell types still lags behind catalyst development. Here, we have developed a bioartificial device comprising cancer-derived exosomes that are loaded with Pd catalysts by a method that enables the controlled assembly of Pd nanosheets directly inside the vesicles. This hybrid system mediates Pd-triggered dealkylation reactions in vitro and inside cells, and displays preferential tropism for their progenitor cells. The use of Trojan exosomes to deliver abiotic catalysts into designated cancer cells creates the opportunity for a new targeted therapy modality; that is, exosome-directed catalyst prodrug therapy, whose first steps are presented herein with the cell-specific release of the anticancer drug panobinostat.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Bioorthogonal Uncaging of Cytotoxic Paclitaxel through Pd Nanosheet-Hydrogel Frameworks

  • Pérez-López, A.M.
  • Rubio-Ruiz, B.
  • Valero, T.
  • Contreras-Montoya, R.
  • Álvarez de Cienfuegos, L.
  • Sebastián, Víctor
  • Santamaría, Jesús
  • Unciti-Broceta, A.
The promising potential of bioorthogonal catalysis in biomedicine is inspiring incremental efforts to design strategies that regulate drug activity in living systems. To achieve this, it is not only essential to develop customized inactive prodrugs and biocompatible metal catalysts but also the right physical environment for them to interact and enable drug production under spatial and/or temporal control. Toward this goal, here, we report the first inactive precursor of the potent broad-spectrum anticancer drug paclitaxel (a.k.a. Taxol) that is stable in cell culture and labile to Pd catalysts. This new prodrug is effectively uncaged in cancer cell culture by Pd nanosheets captured within agarose and alginate hydrogels, providing a biodegradable catalytic framework to achieve controlled release of one of the most important chemotherapy drugs in medical practice. The compatibility of bioorthogonal catalysis and physical hydrogels opens up new opportunities to administer and modulate the mobility of transition metal catalysts in living environs.